argenx stock holds firm after a July 21 earnings beat.
Published on 08/13/2026 at 17:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
argenx stock holds firm after July 21, 2026 results that showed $7.32 in quarterly EPS and $1.54 billion in revenue, both above expectations, while the shares opened at $876.00 on August 13, 2026.
Latest quarter sets the pace
The company reported $7.32 EPS for the quarter, topping the $5.86 consensus by $1.46, and revenue reached $1.54 billion versus the $1.45 billion estimate. That same update also showed a 32.19% net margin and 43.59% return on equity.
Market data on August 13, 2026 put the stock at a $54.80 billion market cap with a 12-month range of $637.04 to $953.58. The 50-day moving average was $882.24 and the 200-day moving average was $820.70, which keeps the shares close to a key technical band.
Consensus stays upbeat
Sell-side coverage remains constructive, with a reported average rating of Moderate Buy and a consensus price target of $1,056.89. The latest note set from August 2026 also showed 18 Buy ratings, two Strong Buy ratings and four Hold ratings.
For investors, the comparison that stands out is simple: $7.32 EPS against $5.86 expected, plus $1.54 billion in sales against $1.45 billion expected. That gap matters more than the headline market cap when the focus is on earnings power and the pace of analyst revisions.
Vyvgart remains central
argenx's lead product, Vyvgart, is the company's FcRn antagonist therapy and the main commercial driver behind the current earnings profile. The product platform remains tied to autoimmune and neuromuscular diseases, which keeps execution on launch momentum and prescribing depth at the center of the story.
Shares and valuation
At $876.00 on August 13, 2026, the stock traded below the 12-month high of $953.58 and above the 12-month low of $637.04. The market cap stood at $54.80 billion, and that leaves valuation support tied to whether the next quarter can keep matching the July 21 beat.
Company details
Company: argenx SE
ISIN: NL0010832176
Ticker: ARGX
Exchange: Nasdaq
Sector / Industry: Health Care / Biotechnology
Index membership: Nasdaq-100
More on argenx stock
The product investors watch most closely is Vyvgart, the company's flagship FcRn therapy. Its role in the latest quarter gives the stock its clearest operational anchor.
